Background
==========

There are numerous causes of fetal death, including genetic conditions, infections, placental abnormalities, and fetal-maternal hemorrhage. Valuable tests for the evaluation of fetal death are perinatal autopsy, placental examination, cytogenetic analysis, and testing for fetal maternal hemorrhage \[[@B1],[@B2]\]. The first trimester of pregnancy, usually defined as the period from fertilization until the 13th week of gestation, is the most sensitive time of development for the conceptus and a relatively high incidence of first trimester spontaneous abortion is reported. Although maternal exposure to certain teratogens and possible immune rejection of the conceptus do occur, the most common cause of first trimester spontaneous abortion is a chromosomal abnormality \[[@B3]-[@B8]\]. Chromosomal abnormalities found in second trimester losses are similar to those found in live births; the most common are trisomies 13, 18, and 21, monosomy X, and sex chromosome polysomies \[[@B9]\]. Second (13--27 weeks) and third trimester (28--42 weeks) fetal death can also be attributed to many other single or multiple causes. Beside fetal anomalies placentation and cord morbidities, or maternal co-morbidities may play a major role. However, a cause-and-effect relationship is often difficult to establish. The most common cause of intrauterine fetal death (IUFD) in the third trimester appears to be umbilical cord accidents \[[@B4]-[@B6]\].

Karyotyping of IUFD samples requires viable cells. As karyotyping fails in up to 40% of the cases due to culturing failure, molecular testing of IUFD samples by Multiplex Ligation-dependent Probe Amplification (MLPA) or Quantitative Fluorescent Polymerase Chain Reaction (QF-PCR), for the detection of the most common aneuploidies, has proven to be very helpful as cell culture is not required \[[@B10],[@B11]\]. The microarray technology already proved its value in post- and prenatal diagnostics as it enables the detection of submicroscopic aberrations (gains and losses) with a very high resolution \[[@B12]-[@B20]\]. Moreover, it overcomes many of the limitations of routine karyotyping \[[@B7],[@B10],[@B21],[@B22]\]. Since January 2010 our diagnostic centre routinely performs array analysis in IUFD samples associated with congenital anomalies after exclusion of the most common aneuploidies. Since February 2012 array analysis is also been performed for IUFD samples without congenital anomalies (and without a common aneuploidy).

In this retrospective study, we evaluated the results of various genetic tests in samples of IUFD from first, second and third trimester pregnancies. Next to the results of traditional karyotyping and QF-PCR, we illustrate the strength of Single Nucleotide Polymorphisms (SNP) array analysis based on genotyping data.

Methods
=======

From January 2010 until August 2012, 417 samples of fetal death *in utero* were investigated. Genetic studies were performed on all IUFD samples either by analysis of material obtained after invasive prenatal testing before induction of labor (amniotic fluid or chorionic villi, N = 57) or by analysis of postpartum obtained tissue of the fetus (fetal skin, placental and/or umbilical cord material, N = 360). All samples were analyzed at the Radboud university medical center in Nijmegen for genetic examination. Gestational age of the pregnancy and clinical information about the fetus were collected from the genetic test request form.

DNA for QF-PCR
--------------

Tissue samples were minced and treated with collagenase to obtain a cell suspension. Subsequently, DNA was isolated following standard procedures by robot (Chemagic Magnetic Separation Module 1 from Chemagen, Baesweiler, Germany).

From chorionic villi, the cytotrophoblast and mesenchymal core fraction were enzymatically dissociated with trypsin/EDTA followed by collagenase treatment. Genomic DNA for QF-PCR was extracted from both villi fractions. DNA was extracted from 1 ml uncultured amniotic fluid using a Chelex based procedure (Instagene Matrix, Bio-Rad Laboratories, Hercules, CA, USA).

DNA for array
-------------

DNA isolated from tissue samples for QF-PCR was also used for array.

From chorionic villi, only DNA isolation from the mesenchymal core fraction was performed for array analysis using the QIAamp DNA Mini Kit (Qiagen Benelux BV, Venlo, the Netherlands), following the instructions of the manufacturer.

From uncultured amniotic fluid, DNA from 6 ml was isolated, using the QIAamp MinElute Virus spin kit (Qiagen Benelux BV, Venlo, the Netherlands) and eluted in 50 μl of elution buffer.

QF-PCR
------

Two different QF-PCR kits were used: tissue samples were tested for aneuploidies of the chromosomes 13, 15, 16, 18, 21, 22, X, or Y (kit Devyser Extend, Cytogen, Sinn, Germany), while chorionic villi and amniotic fluid samples were tested for aneuploidies of the chromosomes 13, 18, 21, X and Y (Aneufast, Genomed Ltd, UK).

Whenever an aneuploidy was detected, cytogenetic evaluation of parental blood followed to study whether the fetal abnormality could be due to a parental rearrangement.

Karyotyping
-----------

In 46 of the 57 chorionic villi or amniotic fluid samples, karyotyping was the first-line test due to the fact that at that time the QF-PCR was not yet implemented as a first-line test for prenatal IUFD samples. Karyotyping was performed following standard procedures.

In three samples, culturing of the fetal material and/or QF-PCR could not be carried out and, therefore, only array analysis was performed.

Array
-----

After a normal QF-PCR or karyotype result, genome wide array analysis was performed on DNA from 168 IUFD samples from fetuses with or without malformations (before February 2012 array was only performed on IUFD samples with malformations or on request, from February 2012 routinely on all IUFD samples).

Seventy one samples were tested using the Affymetrix GeneChip 250 k (NspI) SNP array platform (Affymetrix, Inc, Santa Clara, California, USA), which contains 25-mer oligonucleotides representing a total of 262,264 SNPs (Method, see \[[@B13]\]). Data were analyzed with the CNAG software package \[[@B14]\]. The other 97 array analyses were carried out following the manufacturer's protocols on the high resolution CytoScan HD array platform which contains more than 2.6 million markers, including 750,000 genotype-able SNPs and 1.9 million non-polymorphic probes. Data were analyzed with the Affymetrix Chromosome Analysis Suite (ChAS) software (Affymetrix, Inc, Santa Clara, California, USA). The two major quality control metrics for Affymetrix array are the Median Absolute Pairwise Difference (MAPD) score which applies to copy number probes and the SNP-QC which applies to SNP probes. In our diagnostic setting, the values for these parameters need to be **≤** 0.25 for MAPD and ≥ 0.15 for SNP-QC.

We set the cut-offs for our detection criteria for copy number variants (CNVs) at 20 kb for gains, 10 kb for losses and 1,250 kb for Regions Of Homozygosity (ROH). Our reporting criteria for CNVs depend on the gene content and on the size. Follow-up testing on parental samples is, based on the size of the CNV, performed by array, Fluorescence In Situ Hybridization (FISH) and/or karyotyping. An overview of our recommendations concerning the detection and reporting criteria for diagnostic array results and follow-up testing is shown in Table [1](#T1){ref-type="table"}. The breakpoint positions of each aberrant region were converted to UCSC hg19 (UCSC Genome Browser, release February 2009).

###### 

Recommendations concerning the detection and reporting criteria for diagnostic array results and follow-up testing

  ------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- ------------------ ---
  **Detection criteria**                     **Gain**                                                                                                                                                                                       **Loss**                                            **ROH**             
  Minimum marker count                       10                                                                                                                                                                                             10                                                  500 (SNP probes)    
  Minimum size (kb)                          20                                                                                                                                                                                             10                                                  1250                
  **Reporting criteria**                     **Gene content of CNV**                                                                                                                                                                        **Size of CNV (kb)**                                                    
                                             Known disease gene, matching the phenotype                                                                                                                                                     \<20                                                                    
                                             Known disease gene(s)\*                                                                                                                                                                        \>20                                                                    
                                             No disease gene(s)                                                                                                                                                                             \>100                                                                   
                                             No genes                                                                                                                                                                                       \>500                                                                   
                                             **ROH**                                                                                                                                                                                        **Size of ROH (Mb)**                                                    
  \> 10                                      Genomic Oligoarray and SNP array evaluation tool v2.0 ^\[24\]^ **→** recessive disease causing genes **→** mutation detection                                                                  Positive → Parental mutation carrier analysis                          
  \< 10                                      In case of a specific clinical suspicion for a known syndrome **→** Genomic Oligoarray and SNP array evaluation tool v2.0 ^\[24\]^ →recessive disease causing genes **→** mutation detection   Positive **→** Parental mutation carrier analysis                      
  **Parental testing**                       **Type of CNV**                                                                                                                                                                                **Follow-up test**                                                      
                                             Uncertain                                                                                                                                                                                      Array analysis                                                          
  Clinically relevant:                                                                                                                                                                                                                                                                                             
  \- cytogenetically visible (\> 5--10 Mb)   Karyotyping                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                   
  \- submicroscopic aberration (\<1-10 Mb)   FISH                                                                                                                                                                                                                                                                  
  ------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- ------------------ ---

\*Depending on the referral reason for array, in this case intrauterine fetal death, a certain CNV will sometimes not be reported, even though our general reporting criteria are met. For example, if it concerns a 50 kb loss in an OMIM disease gene that is not involved in embryonic and fetal development. Alternatively, a certain CNV is reported, but in the explanatory text of the array report it is mentioned that this CNV is not very likely causative for the IUFD.

CNVs were classified as (a) benign, (b) likely/probably benign, (c) of uncertain clinical relevance, (d) of unknown clinical significance because of unknown inheritance, (e) likely/possibly clinically relevant or (f) clinically relevant.

A variant was categorized as benign if its full length had been reported in at least three apparently unaffected individuals as listed in the Database of Genomic Variants \[[@B23]\] or our in-house databases containing array data from healthy control individuals (i.e., volunteers, blood donors, etc.). A CNV was likely/probably benign when an identical CNV was inherited from an healthy parent and likely/probably clinically relevant whenever the CNV had been described in a single case report but with well-defined phenotype, specific and relevant to the IUFD. Clinically relevant variants had evidence of pathogenicity according to the published literature, often containing a gene known to be relevant in fetal development or fetal death as listed in the Online Mendelian Inheritance in Man (OMIM) database. Variants that did not meet the criteria for classification as clinically relevant or benign were classified as CNVs of uncertain clinical significance, or as CNVs of unknown clinical significance because of unknown inheritance because parental inheritance could not be determined yet.

In addition to copy number analysis, SNP array data analysis also enabled genotyping of the array data and the detection of homozygous stretches. Regions Of Homozygosity (ROH) with a size \> 10 Mb were evaluated for autosomal recessive conditions in fetuses with a clinical phenotype using a clinical evaluation tool for SNP arrays (Genomic Oligoarray and SNP array evaluation tool v2.0) \[[@B24]\]. This tool systematically searches through relevant databases including the OMIM database, the University of California at Santa Cruz Genome Browser (UCSC), and the National Center for Biotechnology Information (NCBI) database, to rapidly identify disease genes mapping to the ROH to enumerate associated autosomal recessive clinical disorders and their clinical features.

Results
=======

An overview of all samples and diagnostic test results is shown in Figure [1](#F1){ref-type="fig"}.

![Distribution, number and type of aneuploidy detected in the cohort of 417 IUFD samples.](1755-8166-7-6-1){#F1}

QF-PCR/Karyotyping
------------------

In 50 (12.0%) samples an aneuploidy was detected. This was 47.1% (8/17) in first trimester samples, 13.2% (35/265) in second trimester samples, 3.4% (4/116) in third trimester samples, and 15.8% (3/19) in the samples of unknown gestational age. The aneuploidies included trisomy 13 (N = 9), trisomy 18 (N = 4), trisomy 21 (N = 18), monosomy X (N = 12), triploidy (N = 6) and one mosaic trisomy 7 (Figure [2](#F2){ref-type="fig"}).

![**Overview of diagnostic testing in 417 IUFD samples.** Aneuploidy testing (by QF-PCR or karyotyping) is categorized as normal, aneuploidy, not performed or failed. Microarray results are indicated as normal (benign CNV), clinically relevant, unknown (CNV of unknown inheritance), inherited (likely/probably benign CNV) or failed. *Mono X: monosomy X; \*sample tested by QF-PCR and karyotyping; \*\*two samples tested by both QF-PCR and karyotyping.*](1755-8166-7-6-2){#F2}

Karyotyping (N = 46) failed in four (8.7%) amniotic fluid samples. These four samples were from third trimester pregnancies and were contaminated with old blood.

QF-PCR (N = 368) failed in seven samples (1.9%). Two of these were amniotic fluid samples which were contaminated with old blood. In both cases, diagnostic testing could successfully be performed by array. In the first case, also umbilical cord was received and examined, and in the second case amniotic fluid cells could be cultured and used for DNA isolation and array. The QF-PCR test of two skin biopsies failed because DNA was of poor quality due to degradation. We did not obtain interpretable results by QF-PCR in three placenta samples because of maternal cell contamination. In one sample with maternal contamination array was performed, the sample was from a male fetus with an paternally inherited unbalanced translocation t(17;18).

Array
-----

In 168 samples examined by array one test failure (Cytoscan HD) occurred because the DNA was of poor quality due to degradation. Six samples did not meet our quality criteria and were therefore analyzed with an adjusted resolution of 1 Mb.

### Copy number variants (CNVs)

A normal array profile was detected in 136 out of 168 (81.0%) samples. In seven (4.2%) samples, one or more (likely) clinically relevant CNVs were detected (Table [1](#T1){ref-type="table"}), with sizes ranging from 1.1 to 48.0 Mb. To define whether the CNVs had occurred *de novo*, were inherited, or caused by the presence of a parental balanced translocation, additional parental testing was performed in six of the seven samples. Only in case id 60 blood was requested but not yet received. Parental karyotyping was performed in five samples and normal karyotypes were obtained in nine parents. In case id 206, the father appeared to be carrier of a balanced reciprocal translocation 46,XY,t(17;18)(q23;q21.1), as is also indicated in the fetal karyotype in Table [2](#T2){ref-type="table"}. Parental testing was performed by FISH in case id 296 and revealed a normal 22q11.2 FISH pattern in both parents.

###### 

CNVs that are clinically relevant (N = 7)

  **Case id**   **Pregnancy trimester**   **Clinical features**                                    **Array platform**   **Size (Mb)**   **Chromosomal region**   **Start-end Mb position (Hg19)**   **CNV**   **Disease-causing OMIM genes involved (UCSC feb 2009)**
  ------------- ------------------------- -------------------------------------------------------- -------------------- --------------- ------------------------ ---------------------------------- --------- -----------------------------------------------------------
  **60**        first                     Hydrops fetalis                                          CytoScan® HD         8.4             3p24.2p24.3              17269256-25630783                  loss      *THRB*
  **206**       unknown                   MCA                                                      250 k                8.4             17q23.1q25.3             70175362-78598059                  gain      \~ 19 genes\*
  26.8          18q21.2q23                49229300-76115293                                        loss                 \~ 13 genes\*                                                                         
                                                                                                   t(17;18)pat                                                                                                
  **212**       third                     Unilateral talipes calcaneovalgus, unilateral ear tag    250 k                11.8            5p15.2p15.33             81949-11834131                     dn loss   *SDHA, SCL6A19, TERT, SLC6A3, NDUFS6, NSUN2, MTRR, CCT5*
  4.3           5p15.1p15.2               11857228-16124168                                        dn gain              *DNAH5, ANKH*                                                                         
  **274**       second                    Edema (hands and feet)                                   CytoScan® HD         48.0            1q32.1q44                201214014-249224685                dn gain   \~50 genes\*
                1.1                       9p24.3                                                   203862-1293115       dn loss         *DOCK8, KANK1*                                                        
                                                                                                                        37.5            9p13.1p24.3              1293354-38787480                   dn gain   \~30 genes\*
  **296**       second                    Hypertelorism, micrognathia, microencephaly, flat face   CytoScan® HD         3.2             22q11.21                 18644791-21800798                  dn loss   *PRODH, GP1BB, TBX1, COMT, RTN4R, SCARF2, HCF2, SNAP29*
  **309**       first                     Exencephaly                                              CytoScan® HD         18.4            18p11.32p11.1            136227-18521286                    dn loss   *SMCHD1, LPIN2, TGIF, NDUFV2, APCDD1, GNAL, AFG3L2, MC2R*
                                                                                                                        19.3            18q21.32q23              58738938-78014124                  dn gain   *PIGN, TNFRSF11A, BLC2, RTNN, CYB5A, TSHZ1, CTDP1*
  **317**       first                     Hydrops fetalis                                          CytoScan® HD         23.0            9q22.33q33.2             101052575-124018186                dn loss   \~20 genes\*

\*Number of disease-causing OMIM genes \> 10 → genes not specified.

In fifteen (8.9%) samples CNVs (12/15 with sizes \<1 Mb, 3/15 with sizes between 1--1.4 Mb) were detected of unknown inheritance (see Table [3](#T3){ref-type="table"}). Although parental samples were requested for carrier testing, these have not been received so far.

###### 

CNVs of unknown clinical relevance (due to unknown parental inheritance)

  **Case id**   **Pregnancy trimester**   **Clinical features**                                                                          **Array platform**   **Size (kb)**   **Chrom region**   **Start-end Mb position (Hg19)**   **C CNV**   **Ref Seq (and/or disease-causing OMIM) genes involved (UCSC feb 2009)**
  ------------- ------------------------- ---------------------------------------------------------------------------------------------- -------------------- --------------- ------------------ ---------------------------------- ----------- ----------------------------------------------------------------------------------------------------------------
  **2**         second                    Suspect twin to twin transfusion syndrome (TTTS), clenched fist both hands, monozygotic twin   250 k                663             4q34.1             173762947-174426181                loss        *GALNTL6, GALNT7, HMGB2, SAP30, SCRG1*
  **7**         second                    IUGR                                                                                           250 k                447             3q21.2             125498921-125945498                gain        *MIR548I1, FAM86JP, ALG1L, ROPN1B, SLC411A3, ALDH1L1, ALDH1L1-AS1 and AS2*
  **12**        second                    MCA                                                                                            250 k                587             2p12               77036873-77624262                  loss        *LRRTM4*
  **14**        second                    Unknown, recurrent IUFD                                                                        250 k                1,200           6q16.1             95641761-96851236                  gain        *MANEA, FUT9, MANEA-AS1*
  **16**        second                    Hygroma colli                                                                                  250 k                1,400           1q21.1             143570846-144929606                loss        \>10 RefSeq genes\*, mutation analysis for Noonan genes: *NRAS, SHOC2, GBL, RAF1, SOS1, KRAS, PTPN11* negative
  **21**        third                     Hydrocephaly                                                                                   CytoScan® HD         383             16p13.3            3945203-4328143                    loss        *ADCY9, SRL, LOC100507501,TFAP4* (proximal to OMIM gene *CREBBP*)
  **30**        second                    Potter's sequence, renal agenesis, facial dysmorfisms, single palmar crease                    250 k                1,005           1p32.3             53484565-54489583                  gain        \>10 RefSeq genes\* and 3 disease-causing OMIM genes: *SCP2, CPT2, LRP8*
  **34**        unknown                   unknown                                                                                        CytoScan® HD         830             3p24.1             26641410-27471832                  gain        *LRRC3B, NEK10, SLC4A7*
  **39**        second                    None                                                                                           CytoScan® HD         828             Xq28               148839499-149667835                gain        *MAGEA9B, MAGEA9, MAGEA8-AS1, MAGEA8, CXorf40B, LINC00894, MIR2114* and 1 disease-causing OMIM gene: *MAMLD1*
  **47**        second                    None                                                                                           CytoScan® HD         358             18q21.2            52900743-53258705                  gain        *MIR4529* and disease-causing OMIM gene *TCF4*. Duplication *TCF4* confirmed by MLPA.
  **50**        third                     None                                                                                           CytoScan® HD         545             8p21.3p22          18825888-19370744                  loss        *FSD3, LOC100128993, SH2D4A, CSGALNACT1*
  **20**        third                     None                                                                                           CytoScan® HD         490             3q29               196592132-197081797                gain        *SENP5, NCBP2, NCBP2-AS2, PIG2, MFI2, MFI2-AS1, DLG1, DLG1-AS1, MIR4797*
  **55**        second                    None                                                                                           CytoScan® HD         611             16p11.2            29567296-30177917                  loss        \>10 RefSeq genes\* and 3 disease-causing OMIM genes: *KIF22, PRRT2, ALDOA*
  **56**        second                    Unknown                                                                                        CytoScan® HD         767             22q11.21           21033398-21800798                  loss        \>10 RefSeq genes\* and 2 disease-causing OMIM genes: *HCF2, SNPA29*
  **59**        third                     None                                                                                           CytoScan® HD         266             8p23.3             158049-423802                      loss        *RPL23AP53, ZNT596, FAM87A, FBX025*

\*Number of Ref Seq genes \> 10 → genes not specified.

In nine (5.4%) samples a parentally inherited CNV was detected (Table [4](#T4){ref-type="table"}): these were all gains ranging with sizes \< 1 Mb in 8/9 cases and 1.2 Mb in 1/9 cases (6 out of 8 being maternally inherited).

###### 

Inherited CNVs (N = 9)

  **Case id**   **Pregnancy trimester**   **Clinical features**                                                                    **Array platform**   **Size (kb)**   **Chromosomal region**   **Inheritance**   **Start-end Mb position (Hg19)**   **CNV**
  ------------- ------------------------- ---------------------------------------------------------------------------------------- -------------------- --------------- ------------------------ ----------------- ---------------------------------- ---------
  **242**       second                    Recurrent miscarriages, micrognatia                                                      250 k                559             22q12.3                  maternal          31829608-32388222                  gain
  **257**       second                    Unknown                                                                                  250 k                400             1p31.1                   maternal          71586877-71986553                  gain
  **272**       second                    Hydrops fetalis, low-set ears, Pierre Robin Sequence (PRS)                               CytoScan® HD         303             Xq24                     maternal          118733984-119037053                gain
  **280**       second                    Unknown                                                                                  CytoScan® HD         251             6q27                     paternal          169570833-169822659                gain
  **281**       second                    Mild facial dysmorfic features, hypertelorism, long philtrum                             CytoScan® HD         1,200           1q43                     maternal          236830156-238009186                gain
  **289**       second                    Agenesis of the corpus callosum (ACC), hydrops fetalis, ascites, mild ventriculomegaly   CytoScan® HD         260             9q21.11                  maternal          71570080-71842392                  gain
  **316**       second                    Unknown                                                                                  CytoScan® HD         367             16p13.3                  maternal          5393095-5760407                    gain
  **359**       second                    None (recurrent miscarriages)                                                            CytoScan® HD         990             7q11.21                  paternal          65329349-66417018                  gain
  **65**        second                    Unknown (macerated fetus)                                                                CytoScan® HD         294             Xp22.31                  paternal          8439472-8733564                    gain

An overview of all array results is shown in Figure [3](#F3){ref-type="fig"}.

![Overview of array results: type and number of CNVs detected in 168 samples with IUFD.](1755-8166-7-6-3){#F3}

### Regions of Homozygozity (ROH)

In 25 samples, one or more autosomal ROHs were detected with a size ≥ 5 Mb. From 11 of these samples fetal clinical features were known. By using the online SNP array evaluation tool \[[@B24]\], all genes with recessive inheritance were enumerated to map with the clinical features. In one of these samples (case id. 336), a homozygous mutation in a recessive disease gene was detected. Case id. 336 is a cord biopsy sample from a fetus, from consanguineous parents, that died at 14 weeks of gestation. Postpartum clinical features mentioned on the request form were meningo-encephalocele, a single umbilical artery and suspect for Meckel-Grüber syndrome. Meckel-Grüber syndrome is an autosomal recessive, early embryonic multi-systemic disorder (MKS: OMIM 249000). So far, nine different loci have been mapped, including the *CEP290* gene. DNA isolated from a cord biopsy showed a normal male profile with QF-PCR and array. However, 12.5% homozygosity of the autosomal genome was detected, including a pericentromeric segment of \~80 Mb on chromosome 12 encompassing \>50 genes, among which the *CEP290* gene (Figure [4](#F4){ref-type="fig"}). Subsequent mutation analysis of this gene led to the identification of a pathogenic homozygous missense mutation c.3418G \> T. Both parents appeared to be heterozygous carrier of this mutation.

![**A region of homozygosity in chromosome 12, including the*CEP290*gene.**](1755-8166-7-6-4){#F4}

Discussion and conclusions
==========================

In the present study, we evaluated different genetic tests (QF-PCR, karyotyping and array analysis) in the examination of IUFD samples. Our results show that a common aneuploidy was detected in 12% of the samples which is comparable to a previous report of Korteweg et al. \[[@B2]\] who showed 13% chromosomal abnormalities in a heterogeneous cohort of fetal deaths. The percentage of aneuploidies was highest (47%) in first trimester pregnancies. This is in line with the reported incidence of 30-60% of chromosomal anomalies causing early fetal demise \[[@B24]-[@B28]\]. Although cost aspects were not evaluated in our study, aneuploidy detection is cheaper by QF-PCR than by array and therefore QF-PCR analysis is the preferred first tier technique before array analysis to exclude the most common aneuploidies, in particular in case of a first and second trimester IUFD.

The highest incidence of test failures occurred in amniotic fluid samples because of sample contamination. In 2011, we therefore changed our strategy and asked gynecologists to send a fetal biopsy in cases of IUFD instead of amniotic fluid. The quantity of DNA obtained from fetal tissue is usually sufficient, it is clean and therefore suitable for testing by both QF-PCR and array analysis and additional sequencing of single genes in case of a suspected monogenic disorder.

In our cohort with a normal QF-PCR result, a clinically relevant CNV was detected by array in 4.2% of the samples, varying in size from 1.1 to 48.0 Mb and all concerning fetuses with malformations. This is lower than reported in literature. However, in these papers, the genome-wide prevalence of CNVs was examined in truly unexplained stillbirth, resulting in an overall detection ranging from 8-13% \[[@B11],[@B29]\]. Retrospective studies in fetuses with multiple malformations also obtained a detection rate of causative imbalances from 8 to 15%, including common aneuploidies, by using array \[[@B7],[@B30]-[@B32]\]. Our cohort tested by array, however, consisted of a heterogeneous group of fetal deaths, excluding a common aneuploidy which could clarify our lower detection rate.

Overall, in 8.9% of the samples a CNV was detected with unknown inheritance, most of which (12/15) smaller than 1 Mb in size. In contrast to our routine prenatal diagnostic array workflow, in which it is highly recommended to include parental samples simultaneously, in IUFD genetic analysis, testing of parental samples is requested in our written report only after a likely pathogenic CNV has been detected. To reduce the number of results with CNVs of unknown inheritance and therefore unknown clinical relevance, the maximum effort possible should be undertaken to obtain parental blood for testing. Subsequently, finding the cause of the IUFD is helpful to better understand the cause of death, to more accurately determine the recurrence risks, and to enable possible future testing in some cases.

In eight (4.8%) samples a CNV inherited from a healthy parent was detected. Although not all inherited CNVs can always be classified as benign and without clinical relevance with certainty, they are, dependent on the size and the type of CNV, less likely to directly lead to a clinical phenotype: small CNVs (\< 0.1 Mb) and gains are less likely to be pathogenic than large CNVs (\>1 Mb) and losses, respectively \[[@B33],[@B34]\]. All inherited CNVs in this study were gains ranging in size from \~250 - 1,200 kb, mostly maternally inherited and most likely benign.

The utility of high density SNP arrays is not only useful to rule out potential sample mismatch or false-paternity, but is also used in our laboratory for the examination of regions of homozygosity (ROH) \[[@B16],[@B35]\] and to identify excessive homozygosity, and with specific clinical information the possibility for follow-up diagnostic testing. A nice example in our cohort for demonstrating the power of homozygosity mapping was case id. 336, suspect for Meckel-Grüber syndrome. A homozygous mutation was found in *CEP290*, one of the genes within a large, 80 Mb ROH. Both parents appeared to be heterozygous carriers of this mutation. The Genomic Oligoarray and SNP array evaluation tool enables to evaluate homozygous stretches for autosomal recessive genes in combination with a clinical phenotype making it possible to strategize more focused diagnostic testing \[[@B24]\]. Therefore, we emphasize the need to have detailed phenotypic information to make optimal use of the genotype data from SNP arrays in finding candidate recessive disease genes that may be related to the fetal phenotype.

In concordance with the results of a study of 532 stillbirth samples \[[@B36]\], we conclude that array analysis is more likely to provide an accurate genetic diagnosis than by traditional karyotyping, primarily because of its success with nonviable tissue, making array particularly valuable in the analysis of stillbirths with congenital anomalies. An increased detection rate of chromosomal abnormalities is found when array analysis is used to examine products of conception \[[@B37]\], however, further work is required before the absolute detection rate can be answered.

Nowadays, next-generation sequencing (NGS) is increasingly being used in genetic diagnostics for studying congenital malformations, intellectual disability, and other heterogeneous disorders. Although mutations in genes are known to cause fetal death \[[@B38]\], a systematic genome-wide study has not been performed yet, leaving a large proportion of fetal demise unexplained. It is already demonstrated that NGS not only enables the detection of Single Nucleotide Variation but CNVs as well \[[@B39]\], thus very soon replacing genome wide array analysis in diagnostics. Implementation of NGS for CNV detection and genome/exome wide sequencing in the work-up of IUFD will not only lead to a further improvement of the detection rate, but also to a better fundamental insight in fetal and placental development, and possible maternal interactions.
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